MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:35Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Proton pump inhibitors]]
			[[Category:Antisecretory agents]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #147

2026-05-23T03:51:56Z

parser-claude batch MedTemplate pre-fill, Top 300 #147

New page

{{MedTemplate
| generic = Esomeprazole
| brand = Nexium, Nexium 24HR (OTC)
| structure =
| classes = [[:Category:Proton_pump_inhibitors|Proton pump inhibitor (PPI)]], [[:Category:Antisecretory_agents|Gastric acid suppressant]]
| uses = <vote slug="gerd-use">GERD</vote>, <vote slug="erosive-esophagitis-use">Erosive esophagitis (healing and maintenance)</vote>, <vote slug="h-pylori-use">H. pylori eradication (combination)</vote>, <vote slug="zollinger-ellison-use">Zollinger-Ellison syndrome</vote>, <vote slug="nsaid-ulcer-prophylaxis-use">NSAID-associated ulcer prophylaxis</vote>
| starting_dose = 20-40 mg PO once daily, 30-60 minutes before breakfast
| preparations = 20, 40 mg delayed-release capsules; 2.5, 5, 10, 20, 40 mg oral suspension packets; 20, 40 mg IV
| fda_max = 40 mg/d typical; up to 240 mg/d for Zollinger-Ellison
| pill_id =
| routes = Oral, IV
| onset = Acid suppression within hours; full effect after 3-5 days of dosing
| duration = 24-72 hours per dose (irreversible enzyme binding)
| halflife = ~1.5 hours (plasma); pharmacodynamic effect 24+ hours via target turnover<ref name="nexium-label">FDA Prescribing Information, Nexium (esomeprazole magnesium), AstraZeneca, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021153s050,021957s017,022101s014,021689s029,022101s009lbl.pdf</ref>
| bioavailability = ~64-90% (oral; increases at higher doses and with multi-day dosing)<ref name="nexium-label" />
| pregnancy = Widely used in obstetric reflux; reassuring data.{{citation needed}}
| legal = OTC (20 mg, 14-day course) and [[USLegal:Prescription only|Rx-only]] (higher and longer durations) in US
| mechanism = <vote slug="esomeprazole-mech-claim">Esomeprazole is the S-enantiomer of omeprazole; chiral separation reduces inter-individual variability driven by CYP2C19-mediated R-enantiomer clearance, yielding more consistent acid suppression than racemic omeprazole, particularly in CYP2C19 extensive metabolizers.</vote> Like omeprazole, it is an acid-activated prodrug that covalently and irreversibly binds the H+/K+ ATPase. CYP2C19 PGx remains clinically relevant for both<ref name="cpic-ppi-cyp2c19">CPIC Guideline for CYP2C19 and Proton Pump Inhibitors, 2020. https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/</ref>.
}}

== References ==
<references />

Esomeprazole - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #147